このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発性多発性硬化症患者の注射治療を評価する NIS (AIOLOS)

2026年11月13日 更新者:Novartis Pharmaceuticals

再発性多発性硬化症患者における注射治療(オファツムマブ、酢酸グラチラマー、インターフェロンβ1)を評価する非介入研究[AIOLOS]

This is an observational, non-interventional, multicenter, open-label study in patients being treated with any approved injectable or selected oral DMT for RMS in Germany.

Prospective, primary data will be collected via questionnaires and an electronic case report form (eCRF) over a period of up to four years. Additionally, medical history of participants will be collected including disease duration, laboratory values, EDSS, MRI parameters and relapses.

調査の概要

詳細な説明

The prerequisite for participation in this observational study is the independent decision of the treating physician and patient to start an approved injectable or oral DMT for RMS as routine medical treatment. This decision must have been made prior to enrollment in this study.

Cohort 1: The prospective observational period per patient in the core part will be up to approx. two years from the time of consent (2 years +2 months visit window). If a patient re-consents to the extension part, then the prospective extension observational period will be additional approx. two years, resulting in a total observational period (prospectively for the core and extension part & retrospectively for the potential gap between core and extension part) of approx. 4 years (+ 2 month visit window).

Cohort 2: The prospective observational period per patient will be up to approx. two years from the time of consent (2 years + 2 months visit window).

The observational period will not be dictated by the protocol. The follow-up documentation will take place at a frequency defined as per investigator's discretion. The diagnostic or monitoring procedures are only those ordinarily applied to the therapeutic strategy and to routine clinical care, can be performed as telemedicine visits and will take place as per investigator's discretion.

研究の種類

観察的

入学 (推定)

800

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Novartis Pharmaceuticals

研究場所

      • Aalen、ドイツ、73433
        • 募集
        • Novartis Investigative Site
      • Altenholz、ドイツ、24161
        • 募集
        • Novartis Investigative Site
      • Alzey、ドイツ、55232
        • 引きこもった
        • Novartis Investigative Site
      • Augsburg、ドイツ、86150
        • 募集
        • Novartis Investigative Site
      • Bamberg、ドイツ、96047
        • 積極的、募集していない
        • Novartis Investigative Site
      • Bayreuth、ドイツ、95445
        • 積極的、募集していない
        • Novartis Investigative Site
      • Bayreuth、ドイツ、95444
        • 募集
        • Novartis Investigative Site
      • Bergneustadt、ドイツ、51702
        • 募集
        • Novartis Investigative Site
      • Bergneustadt、ドイツ、51702
        • 引きこもった
        • Novartis Investigative Site
      • Berlin、ドイツ、12163
        • 募集
        • Novartis Investigative Site
      • Berlin、ドイツ、12099
        • 募集
        • Novartis Investigative Site
      • Berlin、ドイツ、14057
        • 募集
        • Novartis Investigative Site
      • Berlin、ドイツ、10437
        • 積極的、募集していない
        • Novartis Investigative Site
      • Berlin、ドイツ、10713
        • 積極的、募集していない
        • Novartis Investigative Site
      • Berlin、ドイツ、12099
        • 積極的、募集していない
        • Novartis Investigative Site
      • Berlin、ドイツ、12099
        • 完了
        • Novartis Investigative Site
      • Berlin、ドイツ、12351
        • 完了
        • Novartis Investigative Site
      • Berlin、ドイツ、13357
        • 引きこもった
        • Novartis Investigative Site
      • Berlin、ドイツ、14169
        • 積極的、募集していない
        • Novartis Investigative Site
      • Bochum、ドイツ、44791
        • 募集
        • Novartis Investigative Site
      • Bochum、ドイツ、44787
        • 募集
        • Novartis Investigative Site
      • Bogen、ドイツ、94327
        • 募集
        • Novartis Investigative Site
      • Bonn、ドイツ、53111
        • 募集
        • Novartis Investigative Site
      • Braunschweig、ドイツ、38100
        • 募集
        • Novartis Investigative Site
      • Bremen、ドイツ、28195
        • 完了
        • Novartis Investigative Site
      • Böblingen、ドイツ、71032
        • 募集
        • Novartis Investigative Site
      • Chemnitz、ドイツ、09117
        • 募集
        • Novartis Investigative Site
      • Coburg、ドイツ、96450
        • 募集
        • Novartis Investigative Site
      • Crailsheim、ドイツ、74564
        • 募集
        • Novartis Investigative Site
      • Dessau、ドイツ、06846
        • 積極的、募集していない
        • Novartis Investigative Site
      • Dillingen Saar、ドイツ、66763
        • 募集
        • Novartis Investigative Site
      • Dortmund、ドイツ、44137
        • 募集
        • Novartis Investigative Site
      • Dresden、ドイツ、01067
        • 積極的、募集していない
        • Novartis Investigative Site
      • Dresden、ドイツ、01097
        • 募集
        • Novartis Investigative Site
      • Duisburg、ドイツ、47138
        • 募集
        • Novartis Investigative Site
      • Duisburg、ドイツ、47138
        • 引きこもった
        • Novartis Investigative Site
      • Düsseldorf、ドイツ、40211
        • 募集
        • Novartis Investigative Site
      • Düsseldorf、ドイツ、40625
        • 募集
        • Novartis Investigative Site
      • Düsseldorf、ドイツ、40211
        • 完了
        • Novartis Investigative Site
      • Eisleben Lutherstadt、ドイツ、06295
        • 募集
        • Novartis Investigative Site
      • Eltville、ドイツ、65343
        • 募集
        • Novartis Investigative Site
      • Erbach im Odenwald、ドイツ、64711
        • 募集
        • Novartis Investigative Site
      • Erfurt、ドイツ、99099
        • 募集
        • Novartis Investigative Site
      • Erfurt、ドイツ、99096
        • 募集
        • Novartis Investigative Site
      • Erlangen、ドイツ、91054
        • 募集
        • Novartis Investigative Site
      • Essen、ドイツ、45257
        • 募集
        • Novartis Investigative Site
      • Essen、ドイツ、45138
        • 募集
        • Novartis Investigative Site
      • Fulda、ドイツ、36037
        • 募集
        • Novartis Investigative Site
      • Fulda、ドイツ、36037
        • 完了
        • Novartis Investigative Site
      • Giessen、ドイツ、35392
        • 募集
        • Novartis Investigative Site
      • Gladenbach、ドイツ、35075
        • 募集
        • Novartis Investigative Site
      • Hagen、ドイツ、58095
        • 積極的、募集していない
        • Novartis Investigative Site
      • Hamburg、ドイツ、20249
        • 募集
        • Novartis Investigative Site
      • Hamburg、ドイツ、22179
        • 募集
        • Novartis Investigative Site
      • Hanover、ドイツ、30625
        • 募集
        • Novartis Investigative Site
      • Höxter、ドイツ、37671
        • 募集
        • Novartis Investigative Site
      • Itzehoe、ドイツ、25524
        • 引きこもった
        • Novartis Investigative Site
      • Kaiserslautern、ドイツ、67655
        • 完了
        • Novartis Investigative Site
      • Karlsruhe、ドイツ、76133
        • 募集
        • Novartis Investigative Site
      • Karlsruhe、ドイツ、76133
        • 引きこもった
        • Novartis Investigative Site
      • Lünen、ドイツ、44534
        • 引きこもった
        • Novartis Investigative Site
      • Magdeburg、ドイツ、39104
        • 募集
        • Novartis Investigative Site
      • Marburg、ドイツ、35037
        • 完了
        • Novartis Investigative Site
      • Merzig、ドイツ、66663
        • 募集
        • Novartis Investigative Site
      • Mettmann、ドイツ、40822
        • 完了
        • Novartis Investigative Site
      • Minden、ドイツ、32429
        • 完了
        • Novartis Investigative Site
      • Montabaur、ドイツ、56410
        • 完了
        • Novartis Investigative Site
      • Muenster-Hiltrup、ドイツ、48165
        • 募集
        • Novartis Investigative Site
      • Mülheim、ドイツ、45468
        • 引きこもった
        • Novartis Investigative Site
      • München、ドイツ、80939
        • 募集
        • Novartis Investigative Site
      • München、ドイツ、81675
        • 積極的、募集していない
        • Novartis Investigative Site
      • Münster、ドイツ、48149
        • 募集
        • Novartis Investigative Site
      • Neuruppin、ドイツ、16816
        • 積極的、募集していない
        • Novartis Investigative Site
      • Nuremberg、ドイツ、90491
        • 引きこもった
        • Novartis Investigative Site
      • Oldenburg、ドイツ、26121
        • 募集
        • Novartis Investigative Site
      • Osnabrück、ドイツ、49074
        • 募集
        • Novartis Investigative Site
      • Pforzheim、ドイツ、75172
        • 募集
        • Novartis Investigative Site
      • Potsdam、ドイツ、14471
        • 完了
        • Novartis Investigative Site
      • Remscheid、ドイツ、42853
        • 募集
        • Novartis Investigative Site
      • Rostock、ドイツ、18057
        • 完了
        • Novartis Investigative Site
      • Rüdersdorf、ドイツ、15562
        • 積極的、募集していない
        • Novartis Investigative Site
      • Rülzheim、ドイツ、76761
        • 募集
        • Novartis Investigative Site
      • Salzatal、ドイツ、06198
        • 募集
        • Novartis Investigative Site
      • Schiltach、ドイツ、77761
        • 募集
        • Novartis Investigative Site
      • Schneverdingen、ドイツ、29640
        • 募集
        • Novartis Investigative Site
      • Siegen、ドイツ、57076
        • 積極的、募集していない
        • Novartis Investigative Site
      • Siegen、ドイツ、57076
        • 募集
        • Novartis Investigative Site
      • Sinsheim、ドイツ、74889
        • 募集
        • Novartis Investigative Site
      • Stadtroda、ドイツ、07646
        • 募集
        • Novartis Investigative Site
      • Stuttgart、ドイツ、70176
        • 募集
        • Novartis Investigative Site
      • Stuttgart、ドイツ、70174
        • 積極的、募集していない
        • Novartis Investigative Site
      • Stuttgart、ドイツ、70182
        • 完了
        • Novartis Investigative Site
      • Tirschenreuth、ドイツ、95643
        • 募集
        • Novartis Investigative Site
      • Trier、ドイツ、54292
        • 募集
        • Novartis Investigative Site
      • Tübingen、ドイツ、72076
        • 募集
        • Novartis Investigative Site
      • Velbert、ドイツ、42551
        • 募集
        • Novartis Investigative Site
      • Weil der Stadt、ドイツ、71263
        • 募集
        • Novartis Investigative Site
      • Witten、ドイツ、58452
        • 募集
        • Novartis Investigative Site
    • Baden-Wurttemberg
      • Albstadt、Baden-Wurttemberg、ドイツ、72458
        • 募集
        • Novartis Investigative Site
      • Hettingen、Baden-Wurttemberg、ドイツ、72513
        • 募集
        • Novartis Investigative Site
      • Hettingen、Baden-Wurttemberg、ドイツ、72513
        • 完了
        • Novartis Investigative Site
      • Mannheim、Baden-Wurttemberg、ドイツ、68163
        • 募集
        • Novartis Investigative Site
      • Nagold、Baden-Wurttemberg、ドイツ、72202
        • 募集
        • Novartis Investigative Site
      • Schwetzingen、Baden-Wurttemberg、ドイツ、68723
        • 募集
        • Novartis Investigative Site
      • Schwäbisch Hall、Baden-Wurttemberg、ドイツ、74523
        • 募集
        • Novartis Investigative Site
    • Bavaria
      • Bamberg、Bavaria、ドイツ、96052
        • 積極的、募集していない
        • Novartis Investigative Site
      • Dillingen an der Donau、Bavaria、ドイツ、89407
        • 積極的、募集していない
        • Novartis Investigative Site
      • Munich、Bavaria、ドイツ、81241
        • 引きこもった
        • Novartis Investigative Site
      • Munich、Bavaria、ドイツ、81829
        • 引きこもった
        • Novartis Investigative Site
      • Neuburg A.d. Donau、Bavaria、ドイツ、86633
        • 積極的、募集していない
        • Novartis Investigative Site
      • Regensburg、Bavaria、ドイツ、93059
        • 引きこもった
        • Novartis Investigative Site
      • Unterhaching、Bavaria、ドイツ、82008
        • 積極的、募集していない
        • Novartis Investigative Site
      • Untermeitingen、Bavaria、ドイツ、86836
        • 募集
        • Novartis Investigative Site
      • Wolfratshausen、Bavaria、ドイツ、82515
        • 引きこもった
        • Novartis Investigative Site
    • Brandenburg
      • Falkensee、Brandenburg、ドイツ、14612
        • 引きこもった
        • Novartis Investigative Site
    • Hesse
      • Bad Homburg、Hesse、ドイツ、61348
        • 募集
        • Novartis Investigative Site
      • Frankfurt am Main、Hesse、ドイツ、65929
        • 積極的、募集していない
        • Novartis Investigative Site
      • Frankfurt am Main、Hesse、ドイツ、60313
        • 完了
        • Novartis Investigative Site
      • Marburg、Hesse、ドイツ、35043
        • 積極的、募集していない
        • Novartis Investigative Site
    • Lower Saxony
      • Hanover、Lower Saxony、ドイツ、30161
        • 積極的、募集していない
        • Novartis Investigative Site
      • Hanover、Lower Saxony、ドイツ、30449
        • 完了
        • Novartis Investigative Site
      • Wildeshausen、Lower Saxony、ドイツ、27793
        • 積極的、募集していない
        • Novartis Investigative Site
    • North Rhine-Westphalia
      • Cologne、North Rhine-Westphalia、ドイツ、50935
        • 募集
        • Novartis Investigative Site
      • Cologne、North Rhine-Westphalia、ドイツ、51063
        • 引きこもった
        • Novartis Investigative Site
      • Dortmund、North Rhine-Westphalia、ドイツ、44287
        • 募集
        • Novartis Investigative Site
      • Düsseldorf、North Rhine-Westphalia、ドイツ、40225
        • 募集
        • Novartis Investigative Site
      • Essen、North Rhine-Westphalia、ドイツ、45134
        • 引きこもった
        • Novartis Investigative Site
      • Gelsenkirchen、North Rhine-Westphalia、ドイツ、45894
        • 募集
        • Novartis Investigative Site
      • Meerbusch、North Rhine-Westphalia、ドイツ、40667
        • 募集
        • Novartis Investigative Site
      • Münster、North Rhine-Westphalia、ドイツ、48165
        • 引きこもった
        • Novartis Investigative Site
      • Oer-Erkenschwick、North Rhine-Westphalia、ドイツ、45739
        • 引きこもった
        • Novartis Investigative Site
      • Siegen、North Rhine-Westphalia、ドイツ、57072
        • 積極的、募集していない
        • Novartis Investigative Site
    • Rhineland-Palatinate
      • Ingelheim、Rhineland-Palatinate、ドイツ、55218
        • 引きこもった
        • Novartis Investigative Site
    • Saarland
      • Saarlouis、Saarland、ドイツ、66740
        • 引きこもった
        • Novartis Investigative Site
    • Saxony
      • Chemnitz、Saxony、ドイツ、09117
        • 積極的、募集していない
        • Novartis Investigative Site
      • Dresden、Saxony、ドイツ、01307
        • 募集
        • Novartis Investigative Site
      • Görlitz、Saxony、ドイツ、02828
        • 募集
        • Novartis Investigative Site
      • Leipzig、Saxony、ドイツ、04103
        • 完了
        • Novartis Investigative Site
      • Leipzig、Saxony、ドイツ、04315
        • 積極的、募集していない
        • Novartis Investigative Site
    • Saxony-Anhalt
      • Altmark、Saxony-Anhalt、ドイツ、39629
        • 引きこもった
        • Novartis Investigative Site
      • Halle、Saxony-Anhalt、ドイツ、06120
        • 募集
        • Novartis Investigative Site
      • Halle、Saxony-Anhalt、ドイツ、06112
        • 募集
        • Novartis Investigative Site
    • Thuringia
      • Altenburg、Thuringia、ドイツ、04600
        • 完了
        • Novartis Investigative Site
      • Altenburg、Thuringia、ドイツ、04600
        • 引きこもった
        • Novartis Investigative Site
      • Jena、Thuringia、ドイツ、07740
        • 募集
        • Novartis Investigative Site
      • Mühlhausen、Thuringia、ドイツ、99974
        • 積極的、募集していない
        • Novartis Investigative Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~100年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

サンプリング方法

非確率サンプル

調査対象母集団

patients with planned initiation or initiation within the past 14 days with an approved injectable or oral DMT for MS as routine medical treatment

説明

Cohort 1 Inclusion Criteria:

  1. Signed informed consent must be obtained prior to participation in the study
  2. Male or female patients aged ≥18 years at enrollment
  3. Diagnosis of MS according to the 2017 revised McDonald criteria (Thompson et al 2018b)
  4. RMS with active disease as defined by Lublin et al. (2014)
  5. Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment
  6. Disability status at enrollment with an EDSS score of 0 to 2.5 (inclusive)
  7. Planned initiation or initiation within the past 14 days with an approved injectable DMT for MS as routine medical treatment

Cohort 2 Inclusion Criteria:

  1. Signed informed consent must be obtained prior to participation,

  2. Male or female patients aged ≥18 years at enrollment,

  3. Diagnosis of MS according to the 2024 revised McDonald criteria (Montalban et al., 2025),

  4. RMS with active disease as defined by Lublin et al. (2014) ,

  5. Max. 1 relapse during the previous year and max. 2 relapses during the previous two years prior to enrollment,

  6. Disability status at enrollment with an EDSS score of 0 to 3.0 (inclusive),

  7. Planned initiation or initiation within the past 14 days with an approved injectable or oral DMT for MS as routine medical treatment:

    • Ofatumumab: only naïve patients or patients previously treated with max. one DMT other than ofatumumab
    • IFN-β1, GA, teriflunomide, DMF or DRF: only naïve patients

Cohort 1 Exclusion Criteria:

  1. Patients being treated outside of the approved label
  2. > 5 years since first symptom(s) (leading to MS diagnosis) at enrollment
  3. Previous therapy with any DMT for the treatment of MS prior to enrollment (except within the past 14 days with an approved injectable DMT for MS as routine medical treatment; see Inclusion criteria #7)
  4. Relapse prior to enrollment which has led to a severe deficit relevant to everyday life upon discretion of the investigator after exhaustion of the relapse therapy
  5. Poor recovery from the first two relapses prior to enrollment upon discretion of the investigator
  6. EDSS Functional System Score "Pyramidal Functions" ≥ 2 at enrollment
  7. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab

Cohort 2 Exclusion Criteria:

  1. Patients being treated outside of the approved label,
  2. >5 years since first symptom(s) (leading to MS diagnosis) at enrollment,
  3. Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with Ofatumumab,
  4. Patients being previously enrolled in cohort 1 are not eligible to be enrolled into cohort 2

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 観測モデル:COHORT
  • 時間の展望:PROSPECTIVE

コホートと介入

グループ/コホート
介入・治療
Ofatumumab

Patients treated with ofatumumab

There is no treatment allocation. Patients administered ofatumumab by prescription that have started as routine medical treatment will be enrolled.

Standard of Care (SoC)

Patients treated with either interferon β1 (IFN-β1), glatiramer acetate (GA), teriflunomide, dimethyl fumarate (DMF) or diroximel fumarate (DRF)

There is no treatment allocation. Patients administered glatiramer acetate by prescription that have started as routine medical treatment will be enrolled.

There is no treatment allocation. Patients administered interferon β1 by prescription that have started as routine medical treatment will be enrolled.

There is no treatment allocation. Patients administered teriflunomide by prescription that have started as routine medical treatment will be enrolled.

There is no treatment allocation. Patients administered dimethyl fumarate (DMF) by prescription that have started as routine medical treatment will be enrolled.

There is no treatment allocation. Patients administered diroximel fumarate (DRF) by prescription that have started as routine medical treatment will be enrolled.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of patients who continue to receive their baseline treatment
時間枠:Month 24

Proportion of patients who continue to receive their baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)]

Month 24

二次結果の測定

結果測定
メジャーの説明
時間枠
Proportion of patients who continue to receive their baseline treatment
時間枠:Month 12

Proportion of patients who continue to receive their baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)]

Month 12
Time to event analysis for retention time on baseline treatment
時間枠:From Baseline to event, up to 24 months

Time-to-event analysis for retention time on baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)]

From Baseline to event, up to 24 months
Impact of first-line treatment on health economy
時間枠:Baseline, month 6, month 12, month 18 and month 24

Mean annual health care resource utilization cost, annual direct medical costs, annual direct nonmedical costs and annual indirect costs as measured by MS Health Resource Utilization Survey [MS-HRS]

MS-HRS is a 24-item questionnaire covers societal resource use, regardless of the issue of reimbursement, as well as impact of the disease on work, family and leisure. With the help of this questionnaire a monetary value can be assigned to e.g. the stage of MS, a relapse or a therapy.

Baseline, month 6, month 12, month 18 and month 24
Fatigue Symptoms and Impact Questionnaire-RMS
時間枠:Baseline, month 3, month 6, month 12, month 18, month 24

Fatigue Symptoms and Impact Questionnaire-RMS [FSIQ-RMS]

The FSIQ-RMS comprises 20 items organized in a conceptual framework with 2 symptom domains (energy, muscle weakness) and 7 impact domains (daily activities, cognition, emotions, physical impact, self-care, sleep, social impact) in order to measure fatigue symptoms and impacts in relapsing multiple sclerosis.

A scoring algorithm standardizes scores on both the symptoms domain (daily and weekly) and impacts subdomains (weekly) to a 0 to 100 scale, with higher scores indicating more severe symptoms and impacts. There is no single summary score across the FSIQ-RMS instrument, but rather 1 symptoms score and 3 impacts subdomain scores.

Baseline, month 3, month 6, month 12, month 18, month 24
Patient Health Questionnaire 8 [PHQ-8]
時間枠:Baseline, month 3, month 6, month 12, month 18, month 24

The PHQ-8 is a valid diagnostic and severity measure for depressive disorders. It consists of eight items, each of which is scored 0 to 3, providing a 0 to 24 severity score. Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively.

Baseline, month 3, month 6, month 12, month 18, month 24
Generalized Anxiety Disorder Scale 7 [GAD-7]
時間枠:Baseline, month 3, month 6, month 12, month 18, month 24

The GAD-7 is a validated 7-item anxiety scale to diagnose generalized anxiety disorder. Each of the items is scored 0 to 3, providing a 0 to 21 severity score. Scores of 5, 10, and 15 represent cutpoints for mild, moderate, and severe anxiety, respectively

Baseline, month 3, month 6, month 12, month 18, month 24
Multiple Sclerosis Impact Scale 29 v2
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24

In this non-interventional study only the nine psychological items will be used to allow conclusions regarding the mental health status of patients with mildly active multiple sclerosis. In its version 2, each item of the MSIS-29 provides four response alternatives, which are rated as 1 to 4. Accordingly, the psychological scale will be described by a raw score between 9 and 36, which will be transformed into a final score between 0 (no impact) and 100 (extreme impact).

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24
Quality of Life in Neurological Disorders [NeuroQoL]
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24

n this non-interventional study the following items will be used: Anxiety, Depression, Ability to Participate in Social Roles and Activities, Positive Affect and Well-Being & Sleep Disturbance. Each response option is assigned a value (e.g.,1=Not at all) and total summed raw score for each respondent are calculated. The total raw score is then translated into a T-score for each participant by using conversion tables. These Tscore are standardized scores with a mean of 50 and a standard deviation (SD) of 10.

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21 and month 24
MS Treatment Concerns Questionnaire [MSTCQ]
時間枠:Baseline, month 3, month 6, month 12, month 18, month 24

MS Treatment Concerns Questionnaire [MSTCQ] is used to assess participants' satisfaction with their treatment injections.

The MSTCQ includes 20 items pertaining satisfaction with the injection system (including issues related to use of the device and preparation of the medication for injection), and AEs related to the patient MS treatment.

All questions have a 5-point response choice, with the responses scored between 1-5. The MSTCQ scores are formed as the sum of all scores. The maximum total score is 100. Lower scores indicate a better state.

Baseline, month 3, month 6, month 12, month 18, month 24
Expanded disability status scale (EDSS)
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

EDSS is a widely used and accepted instrument to evaluate disability status at a given time and, longitudinally, to assess accumulation of disability in clinical studies in MS. The EDSS scale consists of scores in each of seven functional systems (FSs) and an ambulation score that are then combined to determine the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The FSs are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel & Bladder, and Cerebral functions (Fatigue contributes)

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Time to onset of confirmed disability worsening (CDW)
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Time to onset of confirmed disability worsening (CDW) defined as an increase from baseline in EDSS sustained for at least 3 and 6 months, respectively

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Proportion of patients with confirmed disability worsening (CDW)
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Proportion of patients with confirmed disability worsening (CDW) defined as an increase from baseline in EDSS sustained for at least 3 and 6 months, respectively

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Time to onset of confirmed disability improvement (CDI)
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Time to onset of confirmed disability improvement (CDI) defined as a decrease from baseline in EDSS sustained for at least 3 and 6 months

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Proportion of patients with CDI
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Proportion of patients with CDI defined as a decrease from baseline in EDSS sustained for at least 3 and 6 months

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
T1 Gd-enhancing lesions per brain
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

T1 Gd-enhancing lesions per brain to be measured

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Annualized T2 lesion rate
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

New or enlarging T2 lesions per brain and per year (annualized T2 lesion rate)

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Presence of spinal cord lesions
時間枠:Baseline, month 3,month 6, month 9, month 12, month 15, month 18, month 21, month24

Proportion of patients with spinal cord lesions present

Baseline, month 3,month 6, month 9, month 12, month 15, month 18, month 21, month24
Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator.
時間枠:Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24

Proportion of patients with no evidence of disease activity (NEDA3) upon discretion of the investigator. NEDA3 is defined as no 3mCDP, no confirmed MS relapse and no new or enlarging T2 lesions on any MRI scan compared to baseline

Baseline, month 3, month 6, month 9, month 12, month 15, month 18, month 21, month 24
Proportion of patients with no clinical disease activity and no discontinuation of current treatment due to AEs
時間枠:Up to 24 months

Proportion of patients with no clinical disease activity measured by relapse and disease progression and no discontinuation of current treatment due to AEs (excluding pregnancies) and lack of effectiveness

Up to 24 months
Annualized relapse rate
時間枠:Up to 24 months

Annualized relapse rate, defined as the number of confirmed Multiple Sclerosis relapses in a year.

Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection.

Up to 24 months
Time to first relapse
時間枠:Up to 24 months

Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection.

Up to 24 months
Proportion of relapse free patients
時間枠:Up to 24 months

Relapse defined as an appearance of a new neurological abnormality or worsening of previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding clinical demyelinating event. The abnormality must have been present for at least 24 hours and occurred in the absence of fever (< 37.5°C) or a known infection.

Up to 24 months
Serum NfL levels
時間枠:Baseline, month 6, month 12, month 18 and month 24

sNfL levels

Baseline, month 6, month 12, month 18 and month 24
Proportion of patients with low or elevated sNfL levels
時間枠:Baseline, month 6, month 12, month 18 and month 24

Proportion of patients with low or elevated sNfL levels

Baseline, month 6, month 12, month 18 and month 24
Association of selected effectiveness and PRO outcomes with sNfL levels
時間枠:Baseline, month 6, month 12, month 18 and month 24

Association of higher or lower sNfL concentrations with differences in e.g. disease activity, functional status, quality of life, and other PRO-based measures

Baseline, month 6, month 12, month 18 and month 24
Reasons for treatment decisions
時間枠:Up to 24 months

Number of participants by reasons for treatment decisions

Up to 24 months
Number of patients and reasons for discontinuation of treatment
時間枠:Up to 24 months

Number of patients and reasons for discontinuation of treatment classified by category:

  • efficacy (e.g. occurrence of relapse, evidence of disease activity in MRI)
  • safety and tolerability (e.g. injection-site reactions, influenza-like symptoms)
  • or convenience (e.g. inconvenient administration, frequency of injections)
Up to 24 months
Proportion of patients who continue to receive their subsequent treatment
時間枠:Up to 24 months

Proportion of patients who, at a given time over the observational period, continue to receive their subsequent treatment

Up to 24 months
Reasons for and number of treatment interruptions per patient
時間枠:Up to 24 months

Reasons for and number of treatment interruptions per patient to be collected

Up to 24 months
Duration of treatment interruptions per patient
時間枠:Up to 24 months

Duration of treatment interruptions per patient to be collected

Up to 24 months
Number of patients with treatment interruptions
時間枠:Up to 24 months

Number of patients with treatment interruptions to be collected

Up to 24 months
Proportion of drug-related adverse events (AEs)
時間枠:Up to 24 months

Proportion of drug-related adverse events (AEs) including those of special interest (main focus on injection site reactions such as scarring, skin reactions)

Up to 24 months
Persistence of drug-related adverse events (AEs)
時間枠:Up to 24 months

Persistence of drug-related adverse events (AEs) including those of special interest (main focus on injection site reactions such as scarring, skin reactions, influenza-like symptoms)

Up to 24 months
Specific safety assessment of injection related AEs
時間枠:Up to 24 months

Specific safety assessment of injection related AEs. (i.e. injection site reaction AEs vs. injection systemic reaction AEs) summarized by providing the number and percentage of patients with each of the symptoms and pre-specified grouping of symptoms as well as overall.

Up to 24 months
Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons
時間枠:Up to 24 months

Proportion of participants discontinuing treatment due to insufficient effectiveness (lack of efficacy) or tolerability/safety reasons

Up to 24 months
Proportion of sites that share the standardized MRI report form with their radiological colleagues
時間枠:Baseline, month 6, month 12, month 18 and month 24

Proportion of sites that share the standardized MRI report form with their radiological colleagues

Baseline, month 6, month 12, month 18 and month 24
Proportion of standardized MRI report forms and conventional radiologists' reports
時間枠:Baseline, month 6, month 12, month 18 and month 24

Proportion of standardized MRI report forms and conventional radiologists' reports

Baseline, month 6, month 12, month 18 and month 24
Effect of standardized MRI report form on completeness of lesion documentation
時間枠:Baseline, month 6, month 12,1 month 8 and month 24

Proportion of complete MRI lesion documentation using the standardized MRI form versus non-standardized documentation.

Baseline, month 6, month 12,1 month 8 and month 24
Physician's view on added value of standardized MRI report form over conventional radiologists' reports
時間枠:Baseline, month 6, month 12, month 18 and month 24

Proportion of physicians who rate the added value of the standardized MRI report form higher than that of conventional radiologists' reports

Baseline, month 6, month 12, month 18 and month 24
Proportion of patients and physicians that intend to view and use PRO and sNfL results to support patient-physician dialogue
時間枠:Month 6,month 12, month 18 and month 24

Proportion of patients and physicians that intend to view and use PRO and sNfL results to support patient-physician dialogue

Month 6,month 12, month 18 and month 24
Proportion of patients that access their PRO and sNfL result visualizations at least once every 6 months
時間枠:Month 6,month 12, month 18 and month 24

Proportion of patients that access their PRO and sNfL result visualizations at least once every 6 months

Month 6,month 12, month 18 and month 24
Perceived value of PRO and sNfL result visualizations from the perspective of both patient and treating physician on patient-physician dialogue and shared decision making
時間枠:Month 6,month 12, month 18 and month 24

Proportion of patients and physicians who perceive an added value of PRO and sNfL result visualizations on patient-physician dialogue and shared decision making

Month 6,month 12, month 18 and month 24
Age of male and female participants
時間枠:Baseline

Age

Baseline
Number of previous MS relapses of male and female participants
時間枠:Baseline

Number of MS relapses in the 24 months prior baseline

Baseline
Serum NfL levels of male and female patients
時間枠:Baseline, month 6, month 12, month 18 and month 24

sNfL levels

Baseline, month 6, month 12, month 18 and month 24
Proportion of male and female patients who continue to receive their baseline treatment
時間枠:Month 12, Month 24

Proportion of male and female patients who continue to receive their baseline treatment [ofatumumab or other approved disease modifying therapies (IFN-β1, GA, teriflunomide, DMF or DRF)]

Month 12, Month 24
Annualized relapse rate of male and female patients
時間枠:Up to 24 months

Annualized relapse rate, defined as the number of confirmed Multiple Sclerosis relapses in a year of male and female participants

Up to 24 months
Reasons for treatment decisions of male and female patients
時間枠:Up to 24 months

Number of male and female participants by reasons for treatment decisions

Up to 24 months
Quality of Life in Neurological Disorders [NeuroQoL] of male and female patients
時間枠:Baseline, month 3, month 6, month 9, month 12, month15, month 18, month 21 and month 24

T-scores of male and female patients.

  • Anxiety: Score range from 36.4 to 76.8
  • Depression: Score range from 36.9 to 75.0
  • Sleep Disturbance: Score range from 32.0 to 84.2
  • Ability to Participate in Social Roles and Activities: Score range from 24.1 to 60.2
  • Positive Affect and Well-Being: Score range from 26.3 to 68.0 For positive domains (e.g. Well-Being): higher score = better QoL. For symptom domains (e.g. Anxiety): higher scores = worse symptoms
Baseline, month 3, month 6, month 9, month 12, month15, month 18, month 21 and month 24

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Novartis Pharmaceuticals、Novartis Pharmaceuticals

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2022年5月10日

一次修了 (推定)

2029年5月30日

研究の完了 (推定)

2029年5月30日

試験登録日

最初に提出

2022年4月19日

QC基準を満たした最初の提出物

2022年4月19日

最初の投稿 (実際)

2022年4月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月13日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する